Finance / Australia
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
Australia's CSL To Buy Talecris For US$3.1bn
August 2008 | M&A News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
Australia's CSL, the world's second-largest maker of blood plasma products, has agreed to purchase US pharmaceutical Talecris Biotherapeutics Holdings. The company will pay US$3.1bn for North Carolina-based Talecris making it Australia's biggest acquisition by a healthcare company to date. To finance the deal, CSL raised US$1.55bn by selling stock and will pay the remainder with a combination of a loan from Merrill Lynch and cash.